Download PDF

Gastric Cancer

, Volume 10, Issue 2, pp 104–111 | Cite as

Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer

  • Carlo Barone
  • Michele Basso
  • Giovanni Schinzari
  • Carmelo Pozzo
  • Nunziatina Trigila
  • Ettore D'Argento
  • Michela Quirino
  • Antonio Astone
  • Alessandra Cassano
Original article
First Online:
Received:
Accepted:

Abstract

Background

In advanced gastric cancer few data are available on the efficacy or safety of new drug combination regimens after progression following first-line chemotherapy.

Methods

Patients with histologically confirmed advanced gastric cancer and Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than 2, progressing after first-line chemotherapy, were eligible. Patients were treated with docetaxel 75 mg/m2 on day 1 and oxaliplatin 80 mg/m2 on day 2, every 3 weeks, until progression or unacceptable toxicity.

Results

Between May 2002 and April 2005, 38 patients were enrolled. Men accounted for 73.7% of the patients and the median age was 59 years. The primary tumor was not resected in 47.4% of the patients; the peritoneum was the most frequent metastatic site (60.5%). The first-line treatment was cisplatin, epirubicin, and infusional 5-fluorouracil (ECF) in 81.5% of the patients and cisplatin and infusional 5-fluorouracil (CF) in 15.7%. The median number of cycles was 4.3. The treatment was well tolerated, with no toxic deaths. National Cancer Institute (NCI) grade III-IV neutropenia was frequent (26.3%), but no febrile neutropenia was reported. Severe asthenia (15.7%) and severe nausea (15.7%) required dose reductions in 2 patients and treatment discontinuation in another. The overall response rate was 10.5%, and 18 patients (47.3%) experienced disease stabilization (7 of them with significant clinical benefit). Median time to progression was 4.0 months (range, 2–8 months) and median overall survival was 8.1 months (range, 3–26 months). Thirteen patients (34.2%) also received third-line chemotherapy, with an irinotecan-containing regimen, and their median overall survival was higher than that of the other patients (16.3 vs 6.0 months)

Conclusion

The combination of oxaliplatin and docetaxel shows only marginal activity as second-line treatment, but it has a good tolerability profile. This suggests that there is room for optimizing the schedule as well as for planning sequential treatments in gastric cancer.

Key words

Oxaliplatin Docetaxel Gastric cancer Second-line therapy 
Download to read the full article text

References

  1. 1.
    Parkin, DM 2001Global cancer statistics in the year 2000Lancet Oncol25333PubMedCrossRefGoogle Scholar
  2. 2.
    Kelley, JR, Duggan, JM 2003Gastric cancer epidemiology and risk factorsJ Clin Epidemiol5619PubMedCrossRefGoogle Scholar
  3. 3.
    Macdonald, JS 2004Treatment of localized gastric cancerSemin Oncol31456673CrossRefGoogle Scholar
  4. 4.
    Hu, JK, Chen, ZX, Zhou, ZG, Zhang, B, Tian, J, Chen, JP,  et al. 2002Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trialsWorld J Gastroenterol810238PubMedGoogle Scholar
  5. 5.
    Glimelius, B, Ekstrom, K, Hoffman, K, Graf, W, Sjoden, PO, Haglund, U,  et al. 1997Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnn Oncol81638PubMedCrossRefGoogle Scholar
  6. 6.
    Murad, A, Santiago, F, Petroianu, A, Rocha, PR, Rodriguez, MA, Rausch, M 1993Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancerCancer723741PubMedCrossRefGoogle Scholar
  7. 7.
    Pyrrhonen, S, Kuitenen, T, Nyandoto, P, Kouri, M 1995Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBr J Cancer7158791Google Scholar
  8. 8.
    Wils, JA, Klein, HO, Wagener, DJ, Bleiberg, H, Reis, H, Korsten, F,  et al. 1991Sequential high dose methotrexate and fluorouracil combined with doxorubicin — a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative GroupJ Clin Oncol982731PubMedGoogle Scholar
  9. 9.
    Ychou, M, Astre, C, Rouanet, P, Fabre, JM, Saint-Aubert, B, Domergue, J,  et al. 1996A phase II study of fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancerEur J Cancer32A19337PubMedCrossRefGoogle Scholar
  10. 10.
    Preusser, P, Wilke, H, Achterrath, W, Fink, U, Lenaz, L, Heinicke, A,  et al. 1989Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancerJ Clin Oncol713107PubMedGoogle Scholar
  11. 11.
    Cocconi, G, Bella, M, Zironi, S, Algeri, R, Di Costanzo, F, De Lisi, V,  et al. 1994Fluorouracil, doxorubicin and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical ResearchJ Clin Oncol12268793PubMedGoogle Scholar
  12. 12.
    Kelsen, D, Atiq, OT, Saltz, L, Niedzwiecki, D, Ginn, D, Chapman, D,  et al. 1992FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancerJ Clin Oncol105418PubMedGoogle Scholar
  13. 13.
    Kim, NK, Park, YS, Heo, DS, Suh, C, Kim, SY, Park, KC,  et al. 1993A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancerCancer7138138PubMedCrossRefGoogle Scholar
  14. 14.
    Cascinu, S, Labianca, R, Alessandroni, P, Marcellini, M, Silva, RR, Pancera, G,  et al. 1997Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione and filgastrim: a report from the Italian Group for the Study of Digestive Tract CancerJ Clin Oncol15331339PubMedGoogle Scholar
  15. 15.
    Webb, A, Cunningham, D, Scarffe, JH, Harper, P, Norman, A, Joffe, JK,  et al. 1999Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancerJ Clin Oncol8026972Google Scholar
  16. 16.
    Waters, JS, Norman, A, Cunningham, D, Scarffe, JH, Webb, A, Harper, P,  et al. 1999Long term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trialBr J Cancer8026972PubMedCrossRefGoogle Scholar
  17. 17.
    vanhoefer, U, Wagner, T, Lutz, M, Van Cutsem, E, Nordlinger, B, Rause, S,  et al. 2001Randomized phase II study of weekly 24 h infusion of high dose 5-FU+/− folinic acid (HD-FU+/-FA) versus HD-FU/FA/biweekly cisplatin in advanced gastric cancer. EORTC trial 40953Eur J Cancer37S27abstract 88CrossRefGoogle Scholar
  18. 18.
    Barone, C, Corsi, DC, Pozzo, C, Cassano, A, Fontana, T, Noviello, MR,  et al. 1998Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or cisplatin-based regimen: two parallel randomized phase II studiesCancer8214607PubMedCrossRefGoogle Scholar
  19. 19.
    Fatatsuki, K, Wakui, A, Nakao, I, Sakata, Y, Kambe, M, Shimada, Y,  et al. 1994Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study GroupGan To Kagaku Ryoho2110338Google Scholar
  20. 20.
    Pozzo, C, Barone, C, Szanto, J, Padi, E, Peschel, C, Bukki, J,  et al. 2004Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II studyAnn Oncol15177381PubMedCrossRefGoogle Scholar
  21. 21.
    Dank M, Zaluski J, Barone C, Valvere V, Peschel C, Wenczl M, et al. Randomized phase 3 trial of irinotecan (CPT-11+ 5FU/folinic acid (FA) vs CDDP + 5FU in first-line advanced gastric cancer patients. J Clin Oncol 2005;23(S16):(abstract no. 4403)Google Scholar
  22. 22.
    Roth, AD, Maibach, R, Martinelli, G, Fazio, N, Aapro, MS, Pagani, O,  et al. 2000Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and European Institute of Oncology (EIO)Ann Oncol113016PubMedCrossRefGoogle Scholar
  23. 23.
    Constenla, M, Garcia-Arroyo, R, Lorenzo, I, Carrete, N, Campos, B, Palacios, P 2002Docetaxel, 5-fluorouracil and leucovorin as treatment for advanced gastric cancer: results of a phase II studyGastric Cancer51427PubMedCrossRefGoogle Scholar
  24. 24.
    Ajani, JA, Fodor, M, Van Cutsem, E, Tjulandin, S, Moiseyenko, V, Cabial, F,  et al. 2000Multinational randomized phase II study of docetaxel (T) and cisplatin (C) with or without 5-flurouracil (FU) in patients (pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC)Proc Am Soc Clin Oncol19247a(abstract 957)Google Scholar
  25. 25.
    Moiseyenko VM, Ajani JA, Tjulandin SA, Majlis A, Constenla M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). J Clin Oncol 2005;23(S16):(abstract no. 4002)Google Scholar
  26. 26.
    Kim, DY, Kim, JH, Lee, SH, Kim, TY, Heo, DS, Bang, YJ,  et al. 2003Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancerAnn Oncol143837PubMedCrossRefGoogle Scholar
  27. 27.
    Al-Batran, SE, Atmaca, A, Hegewisch-Becker, S, Jaeger, D, Hahnfeld, S, Rummel, HJ,  et al. 2004Phase II trial of biweekly infusional fluorouracil, folinic acid and oxaliplatin in patients with advanced gastric cancerJ Clin Oncol2265863PubMedCrossRefGoogle Scholar
  28. 28.
    De Vita, F, Orditura, M, Matano, E, Bianco, R, Carlomagno, C, Infusino, S,  et al. 2005A phase II trial of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first line treatment of advanced gastric cancer patientsBr J Cancer916449CrossRefGoogle Scholar
  29. 29.
    Louvet, C, Andre, T, Tigaud, JM, Gamelin, F, Douillard, JY, Brunet, R,  et al. 2002Phase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patientsJ Clin Oncol2045438PubMedCrossRefGoogle Scholar
  30. 30.
    Tanaka, R, Ariyama, H, Qin, B, Takii, Y, Baba, E, Mitsugi, K,  et al. 2005In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell linesCancer Chemother Pharmacol55595601Epub 2005 Feb 25PubMedCrossRefGoogle Scholar
  31. 31.
    Agelaki S, Kouroussis C, Mavroudis D, Kalbakis K, Souglakos J, Reppa D, et al. A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer and non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:abstract 443Google Scholar
  32. 32.
    Simon, R, Thall, PF, Ellenberg, SS 1994New designs for selection of treatments to be tested in randomized clinical trialsStat Med1341729PubMedCrossRefGoogle Scholar
  33. 33.
    Kunisaki, C, Imada, T, Yamada, R, Hatori, S, Ono, H, Otsuka, Y,  et al. 2005Phase II study of docetaxel plus cisplatin as second-line combined therapy in patients with advanced gastric carcinomaAnticancer Res2529737PubMedGoogle Scholar
  34. 34.
    Park, SH, Kang, WK, Lee, HR, Park, J, Lee, KE, Lee, SH,  et al. 2004Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimenAm J Clin Oncol2747780PubMedCrossRefGoogle Scholar
  35. 35.
    Polyzos, A, Tsavaris, N, Kosmas, C, Polyzos, K, Giannopoulos, A, Felekouras, E,  et al. 2006Subsets of patients with advanced gastric cancer responding to second-line chemotherapy with docetaxel-cisplatinAnticancer Res26374953PubMedGoogle Scholar
  36. 36.
    Tourningand, C, Andrè, T, Achille, E, Lledo, G, Flesh, M, Mery-Mignard, D,  et al. 2004FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR studyJ Clin Oncol1522937Google Scholar
  37. 37.
    Rothenberg, LM, Amit, LA, Bigelow, RH, Berlin, JD, Marshall, JL, Ramanathan, RK,  et al. 2003Superiority of oxaliplatin and flurouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialJ Clin Oncol21205969PubMedCrossRefGoogle Scholar
  38. 38.
    Grothey, A, Sargent, D, Goldberg, RM, Schmoll, HJ 2004Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatmentJ Clin Oncol22120914PubMedCrossRefGoogle Scholar

Copyright information

© International and Japanese Gastric Cancer Association 2007

Authors and Affiliations

  • Carlo Barone
    • 1
  • Michele Basso
    • 1
  • Giovanni Schinzari
    • 1
  • Carmelo Pozzo
    • 1
  • Nunziatina Trigila
    • 1
  • Ettore D'Argento
    • 1
  • Michela Quirino
    • 1
  • Antonio Astone
    • 1
  • Alessandra Cassano
    • 1
  1. 1.Department of Medical OncologyUniversità Cattolica del Sacro CuoreRomaItaly

Personalised recommendations